Zhitong Finance App News, Shu Taishen (300204.SZ) issued an announcement. Recently, the company's subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. (hereinafter referred to as “Beijetai”) received the administrative license “Notice of Acceptance” from the State Drug Administration. The State Drug Administration agreed to accept the clinical trial application submitted by Beijietai on additional indications of injectable Pomitase α. The acceptance number is: CXSL2601019, application stage: clinical; Indications: treatment of major surgical bleeding.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.